Identifying Potential Qsymia Patients

Qsymia can help you treat many of the patients you see in your practice1,2

Qsymia has been clinically proven to provide effective and well-tolerated treatment for a range of overweight and obese patient types1,2

Qsymia gives a range of overweight and obese patients the power to lose

Qsymia was studied in 2 large trials supporting FDA approval that involved 3754 patients whose BMI was 27 kg/m2 or greater. Average baseline weight of the subjects in the 2 studies was 256 lbs and 227 lbs. Presented here are weight loss and waist circumference reduction in the subset of subjects (N=2076) with a baseline BMI of 27 kg/m2 or greater, and who used study drug for the planned 56-week course of treatment. Patients were randomized to placebo, phentermine 3.75 mg/topiramate 23 mg, phentermine 7.5 mg/topiramate 46 mg, or phentermine 15 mg/topiramate 92 mg. In these trials, it was recommended that patients eat a well-balanced diet and reduce their caloric intake by 500 kcal/day. Your patients’ results may vary depending on their BMI, diet, activity, dose of Qsymia, and other factors.1,2

In a subset analysis, patients with a BMI ≥30 kg/m2 taking the recommended dose of Qsymia lost an average of approximately 10% of their body weight after 1 year.2

 
1

Patient Type 1: Comorbid

Qsymia provides reliable efficacy for obese patients with comorbidities1,2

 

*Statistical significance achieved (type 2 diabetes: P=.0115; hypertension: P<.0001; P values are from Fisher’s exact test).2 Qsymia is not indicated for the treatment of type 2 diabetes, hypertension, dyslipidemia, or depression.

 
BACK TO TOP

2

Patient Type 2: Difficult to Treat

Diffcult-to-treat populations significantly reduced weight in clinical trials1,2

 
BACK TO TOP

3

Patient Type 3: BMI Range

Qsymia helped patients successfully lose weight across a range of BMI1,2

 
BACK TO TOP

Clinically proven weight loss — review the data

Review the results from the two 56-week Qsymia clinical studies1,2

Prescribing and dosing for Qsymia

Initiating therapy and ongoing assessment of Qsymia patients

Important Safety Information

Qsymia is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity or idiosyncrasy to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

VIEW ALL +
Online ordering with convenient home delivery.
You pay only $98 across all doses.§
Exclusively priced for cash patients. Additional shipping and handling costs will apply.
LEARN MORE
LEARN MORE AND SAVE